Spyre's SPY003 Met Its Primary Endpoint
SPY003 met its primary endpoint with a statistically significant reduction of 10.0 points (p<0.0001) from baseline at Week 12 in Robart’s Histopathology Index (RHI) score Secondary endpoints included clinical
Stocks · News reference
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $121 Price Target
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Spyre Therapeutics, Inc. (SYRE)
Filed: 2026-09-08 AccNo: 0001636282-26-000113 Size: 237 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Deutsche Bank Maintains Buy on Spyre Therapeutics, Lowers Price Target to $127
Deutsche Bank analyst David Hoang maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and lowers the price target from $135 to $127.